Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review-Reference-Cited by-同舟云学术

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review

Published:2022-01 Issue: Volume:Volume 15 Page:5-10
ISSN:1178-7015
Container-title:Clinical, Cosmetic and Investigational Dermatology
language:en
Short-container-title:CCID

Author:

Sharaf Baha'^ORCID,AlMasri Rama,Abdel-Razeq Nayef,Salama Osama,Hamad Ibrahim^ORCID,Abunasser Mahmoud^ORCID,Abdel-Razeq Hikmat^ORCID

Publisher

Informa UK Limited

Subject

Dermatology

Reference45 articles.

1. HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

2. Treating cancer with selective CDK4/6 inhibitors

3. Palbociclib and Letrozole in Advanced Breast Cancer

4. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

5. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ribociclib induced vitiligo-like lesions;Indian Journal of Dermatology, Venereology and Leprology;2024-08-30

2. Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication;The Oncologist;2024-01-18

3. Vitiligo‐like depigmentation affecting sun‐exposed areas caused by palbociclib;Photodermatology, Photoimmunology & Photomedicine;2023-11-06

4. Vitíligo asociado a inhibidores de cinasas dependientes de las ciclinas 4 y 6;Piel;2023-10

5. Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation;Frontiers in Oncology;2023-08-24